Home > News > News detail


DualityBio and Tencent Enter into Strategic Collaboration to Explore a Next-Generation Drug R&D Model Powered by AI for Science
DualityBio and BioNTech Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
DualityBio’s Partner Avenzo Therapeutics to Present Preliminary Phase 1 Study Results of AVZO-1418, a Potentially Differentiated EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium
For more information, please
follow the official WeChat public